DexCom earnings beat by $0.03, revenue topped estimates
Mary Beth Dooley, the Principal Executive Officer and Principal Financial (NASDAQ:PFG) Officer of Synlogic, Inc. (NASDAQ:SYBX), a micro-cap biotech company with a market value of $13.22 million, recently sold a portion of her holdings in the company. The stock is currently trading near its 52-week low, having declined 14.29% year-to-date. According to a filing with the Securities and Exchange Commission, Ms. Dooley sold 144 shares of Synlogic’s common stock on April 2, 2025, at a price of $1.20 per share, totaling $172.
This transaction was conducted to cover the tax liabilities associated with the vesting of three restricted stock awards. Following this sale, Ms. Dooley holds 12,901 shares of Synlogic common stock.
In other recent news, Synlogic, Inc. has announced the resignation of Nick Leschly from its board of directors and compensation committee. The resignation was effective immediately and was confirmed to be voluntary. According to an SEC filing, there were no disagreements with the company’s operations, policies, or practices leading to Leschly’s departure. The filing did not specify a successor for his role, leaving the position temporarily vacant. This change is part of the typical dynamics in corporate board management, and the company has not indicated any impact on its strategic direction or operations. Synlogic, previously known as Mirna Therapeutics Inc ., remains active on The NASDAQ Capital Market. The company has not yet made any further announcements regarding new board appointments or updates on its strategic initiatives. Investors and stakeholders are likely to monitor any future developments closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.